Coya Therapeutics is approaching full enrollment in its main clinical trial for COYA 302, an experimental therapy for…
Marisa Horak, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Horak, MS
Filmmaker and University of Virginia graduate Chris Farina had the idea for a documentary about death and dying about 10…
Enrollment of adults with mild-to-moderate amyotrophic lateral sclerosis (ALS) has been completed in a clinical trial testing PHENOGENE-1A as…
People with amyotrophic lateral sclerosis (ALS) who are exposed to high levels of certain pollutants in the years before…
A buildup of microplastics in the nervous system may be linked to a higher risk of developing amyotrophic lateral…
Neurosense Therapeutics is revamping its development plan for PrimeC, the company’s experimental oral therapy for amyotrophic lateral sclerosis…
BTT Medical Institute is launching an early-stage clinical trial to test the safety of the Abreu BTT 700 Temperature…
The ALS Association has awarded Mitochon Pharmaceuticals a $1 million grant to support a Phase 2 clinical trial…
Loneliness and regret are key drivers of mental health distress among people with amyotrophic lateral sclerosis (ALS), according…
People with amyotrophic lateral sclerosis (ALS) who have a history of strenuous exercise tend to develop the disease earlier…